Drug development pipelines are under ever-increasing pressure to deliver more comprehensive data in a shorter timeframe, while reducing costs and making in vitro assay results more relevant to in vivo drug behavior. Assay automation and miniaturization has become essential for the oncology research team in Bayer’s Pharmaceuticals Division.
